|
|
Article: Neurocrine's indiplon profile backed in Ph III.
- Article from:
- Pharma Marketletter
- Article date:
- May 26, 2003
CopyrightCOPYRIGHT 2003 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences of the USA has reported promising Phase III data on its novel hypnotic drug indiplon which suggest that the compound may not be associated with either rebound insomnia or withdrawal effects, two major problems with existing drugs for insomnia.
The company has already presented Phase III results in support of the drug's efficacy and safety in treating insomnia (Marketletters passim). The latest study, however, was specifically designed to look at rebound insomnia and withdrawal following discontinuation of indiplon 10mg or 20mg after 35 consecutive nights of treatment.
In this study, patients were evaluated by using continuous eight ...